A Phase IV Multicenter Study of Iomeron®-400 Used With Multi-detector Computed Tomography Angiography (MDCTA) of the Thoraco-Abdominal Aorta, and the Carotid, Pulmonary, and Peripheral Arteries

This is a Phase IV multicenter, open-label study and is being implemented in order to assess diagnostic image quality of MDCTA in subjects undergoing computed tomography angiography (CTA) of the thoraco-abdominal aorta, and the carotid, pulmonary and peripheral arteries with IOMERON.

Start Date01 Dec 2015

Sponsor / Collaborator

Bracco Diagnostics, Inc.

[+2]

EUCTR2006-002858-29-DE

/ Not yet recruitingNot Applicable

A DOUBLE-BLIND INTER-INDIVIDUAL COMPARISON OF IOMEPROL 300 AND IOMEPROL 400 IN THE ASSESSMENT OF PERFUSION CT OF ADVANCED RENAL CARCINOMA - Perfusion CT of Renal Carcinoma

Start Date27 Oct 2006

Sponsor / Collaborator

Bracco Imaging Deutschland GmbH

100 Clinical Results associated with Iomeprol

100 Translational Medicine associated with Iomeprol

100 Patents (Medical) associated with Iomeprol

742

Literatures (Medical) associated with Iomeprol

01 Jun 2025·JOURNAL OF HYDROLOGY

A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment

Author: Slosarczyk, Kinga ; Dabrowska, Dominika

The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.

01 Apr 2025·HOSPITAL PHARMACY

Validation of an UPLC-PDA Method for the Simultaneous Quantification of Phenol and Iomeprol in a Sterile Parenteral Preparation Used for Coeliac Plexus Block, and Its Application to a Pharmaceutical Stability Study

Article

Author: Deenen, Maarten J. ; Drost-Wijnne, Anne (J.) A. ; Rutgers, Arne A. L. ; van Wezel, Ralph A. C. ; van Suijlekom, Hans (J.) A. ; de Blois, Mieke W. ; Meenks, Sjoerd D. ; Jansen, Willemijn

Objectives: A commonly applied analgesic therapy for patients with severe abdominal pain due to cancer-related pain in the upper abdomen, is coeliac plexus neurolysis (CPN). Herein, a combination product of phenol and an iodine contrast agent are injected simultaneously. The chemical stability of such a combination product is unknown, and no chromatographic method is yet available that describes the simultaneous quantification of phenol and iomeprol. The aim of this study was to develop and validate a stability-indicating UPLC method for the simultaneous quantification of both phenol and iomeprol and to determine the chemical stability of a sterile 100 mg/mL phenol in 350 mg I/mL iomeprol solution for injection during shelf life. Methods: The product was compounded and sterilized in a GMP certified facility. The pharmaceutical analysis was validated by determination of the accuracy, precision, specificity, selectivity, carry-over and linearity. Pharmaceutical product stability was determined before and after sterilization, and during shelf life of 36 months at 25°C ± 2°C. Results: The accuracy for phenol and iomeprol was 97.1% to 99.3% and 100.0% to 100.2%, respectively. The RSD for repeatability and reproducibility for phenol were 0.65% and 1.17%, and for iomeprol 0.61% and 1.49%, respectively. All other tested parameters met the predefined validation criteria. All concentrations at all tested time points remained within ±2% of the initial concentrations for phenol and ±4% for iomeprol. No additional peaks were visible on the chromatograms. Conclusion: A stability-indicating method for the simultaneous quantification of phenol and iomeprol in a parental pharmaceutical preparation was developed and validated. This method was used to demonstrate the chemical stability of a newly developed sterile solution of 100 mg/mL phenol and 350 mg I/mL iomeprol. Chemical product stability was demonstrated during shelf life of up to 36 months.

13 Mar 2025·JOURNAL OF PHYSICAL CHEMISTRY B

Exploring the Adsorption Process of Iodinated Contrast Medias onto Phospholipid Membranes: A Theoretical Toxicity Evaluation Study

Article

Author: Xie, Song ; Liu, Yichang ; Li, Jinlong ; Zhu, Hao ; Gao, Jinsong ; Wang, Liangjie ; Xu, Jing ; Xu, Fengjing ; Liu, Wei

Iodinated contrast media (ICM) molecules are widely used in medical diagnostic imaging. With the increasing consumption of ICM, these compounds have been identified in groundwater and surface water systems. However, the effect of these environmental pollutants on living organisms remains inadequately studied. Herein, we employed molecular dynamics (MD) simulations to investigate the interactions between ICM molecules and the cell membranes. Our findings indicated that the entry behavior of ICM molecules into the membrane is dependent on their chemical structure. The insertion of ICM molecules affects the alignment of phospholipid headgroups and the order parameters of phospholipid tails, resulting in membrane thickness fluctuations. In addition, we observed that the distribution of ICM molecules in the membrane was related to the type of phospholipid. The proportions of phospholipids around the ICM molecules were different. Furthermore, the potential of mean force revealed that different ICM molecules had distinct free energy change characteristics when they transport from an aqueous environment to the membrane center. Some ICM molecules could access the membrane center after overcoming a small energy barrier, suggesting their potential transmembrane ability. This work systematically studied the effects of ICM on cell membranes, providing theoretical evidence for the environmental hazards of ICM.

News (Medical) associated with Iomeprol

27 Jul 2022

·www.prnewswire.com

FDA Grants Import Discretion of Bracco's Iodinated Contrast Medium Iomeron® (iomeprol injection) to Address Supply Shortages

MILAN, July 27, 2022 /PRNewswire/ -- Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron® (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage. Iomeron® (iomeprol injection) is a nonionic iodinated contrast medium for intravascular use in adults in various imaging procedures. Currently registered in over 50 countries in Europe and Asia, it is not approved for use in the United States. The product addresses the need for the most advanced diagnostic imaging standards and will be temporarily available in the U.S. market starting at the end of August 2022. It is manufactured at two Bracco locations: BIPSO GmbH, Singen (Germany), and Patheon Italia S.p.A., Ferentino (Italy). Jeff Fleming, Chief Executive Officer, Bracco Diagnostics Inc., said, "Throughout its 95-year history, Bracco has always put people and innovation at the core of its business, and focused ongoing attention on patient health, safety, and quality of care. We are proud that the company has worked proactively with the FDA to address the shortage of iodinated contrast agents in the U.S. market." For more information on the temporary importation of Iomeron®, click here. About Bracco Imaging Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology dedicated to advancing next generation targeted radiotherapeutics to treat patients who have cancer . Visit: . Bracco Imaging Press Office Duccio Manetti Global Communications Director +39 340 9016191 [email protected] Micaela Colamasi Senior PR Communication Manager +39 340 9775099 [email protected] Bracco Diagnostics Inc. Media Relations (USA) Kimberly Gerweck Senior Manager, Marketing Communications [email protected] D: +1 609-524-2777 SOURCE Bracco Diagnostics Inc.

100 Deals associated with Iomeprol

External Link

KEGG	Wiki	ATC	Drug Bank
D01719	Iomeprol	V08AB10	DB11705

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Contrast agents	China	Spin SpA	19 Jul 2005
Urethral Diseases	Japan	Bracco-Eisai Co., Ltd.	01 Apr 1994
Vascular Diseases	Japan	Bracco-Eisai Co., Ltd.	01 Apr 1994

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis